Navigation Links
Cognitive Skills Focused Curriculum may Lessen Kids' Behavioural Problems

A recent research has found that curriculum focused on cognitive skills may improve child behaviour.

According to a recent study in Annals of the New York Academy of Sciences children who were taught a curriculum that focused on self-discipline and consideration of their own and others' emotions were found to display greater social competence and less behavioural and emotional problems.

The study showed that when teachers taught a particular curriculum to students for 20-30 minutes-per-day, three times-per-week over a six-month period, lower rates of violent behaviour and anxiety/sadness were seen when evaluated a year later compared to children randomized to normal classroom procedures.

"Several complex cognitive processes, such as the ability to cope in stressful situations, are related to the development of the prefrontal areas of the brain starting in the preschool years. We know that deficiencies in the function of these lobes are linked to problems like aggression, depression and attention disorders," says study author Mark Greenberg.

Therefore, the Promoting Alternative Thinking Strategies (PATHS) curriculum, which stimulates cognitive and emotional skills, enhances the child's aptitude to tackle stress and make good choices.

Greenberg offers an example of a simple PATHS skill that helps children comprehend and identify feelings in others.

"Children use 'feeling faces' cards throughout the day to indicate clearly to others what emotions they are experiencing. By labeling the emotions clearly, children learn to recognize them in themselves and others, which will aid them in managing those emotions," says Greenberg.

The main advantage of this curriculum is its defensive nature. Rather than focusing on treating negative behaviours after they have become steady and disturbing, PATHS provides children with coping strategies to stop the development of behavioural
'"/>




Page: 1 2

Related medicine news :

1. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
2. Physical Activity Good For Developing Cognitive Skills
3. Cognitive rehabilitation holds promise for schizophrenic brain function improvements
4. Suicidal Tendencies May Be Treated With Cognitive Therapy
5. Blood Pressure Later Leads to Cognitive Problems
6. Cognitive Behavioral Therapy Seen To Be Effective Against Back Pain
7. Anticholinergic Medicines Result In Cognitive Impairment
8. Cognitive deterioration in the older generation can be prevented by modifying the lifestyle
9. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
10. High Blood Pressure Leads to Rusting of Cognitive Skills
11. Older Women Who Are Avid Watchers of the Tube Have Cognitive Difficulties
Post Your Comments:
Breaking Medicine News(10 mins):Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:REES Announces New Baltimore Office 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2
Other Medicine News:Health News:Texas Cancer Organizations Urge State Legislature to Fully Fund the Cancer Prevention and Research Institute of Texas 2Health News:Gen-Probe Reports Financial Results for First Quarter 2009 2Health News:Gen-Probe Reports Financial Results for First Quarter 2009 3Health News:Gen-Probe Reports Financial Results for First Quarter 2009 4Health News:Gen-Probe Reports Financial Results for First Quarter 2009 5Health News:Gen-Probe Reports Financial Results for First Quarter 2009 6Health News:Gen-Probe Reports Financial Results for First Quarter 2009 7Health News:Gen-Probe Reports Financial Results for First Quarter 2009 8Health News:Gen-Probe Reports Financial Results for First Quarter 2009 9Health News:Gen-Probe Reports Financial Results for First Quarter 2009 10Health News:Gen-Probe Reports Financial Results for First Quarter 2009 11Health News:Gen-Probe Reports Financial Results for First Quarter 2009 12Health News:Gen-Probe Reports Financial Results for First Quarter 2009 13Health News:Gen-Probe Reports Financial Results for First Quarter 2009 14Health News:Gen-Probe Reports Financial Results for First Quarter 2009 15Health News:Gen-Probe Reports Financial Results for First Quarter 2009 16Health News:Gen-Probe Reports Financial Results for First Quarter 2009 17Health News:Gen-Probe Reports Financial Results for First Quarter 2009 18Health News:Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic 2Health News:Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic 3Health News:Chlamydia may play role in a type of arthritis 2
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 6337 1FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 6337 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 6337 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 6337 4Millennium Pharmacy Adds First Client in New England 6334 1Millennium Pharmacy Adds First Client in New England 6334 2Lung cancer experts hold roundtable on new staging guide 61518 1Lung cancer experts hold roundtable on new staging guide 61518 2
Other Medicine Technology:Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5